Nat. Med. 10, 262–267 (2004); published online 22 February 2004
We wish to alert our readers that VX-680, the compound originally reported in the above study, is no longer available from the authors at Vertex Pharmaceuticals due to a post-publication licensing agreement with Merck. However, the compound (referred to by Merck as MK-0457) is being made available through Merck's Investigator-Initiated Studies Program (https://www.merckiisp.com).
Rights and permissions
About this article
Cite this article
Harrington, E., Bebbington, D., Moore, J. et al. Addendum: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 13, 511 (2007). https://doi.org/10.1038/nm0407-511b
Issue Date:
DOI: https://doi.org/10.1038/nm0407-511b
